Results 311 to 320 of about 187,246 (326)

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

The Lancet Oncology, 2018
Youn H. Kim, M. Bagot, L. Pinter-Brown, A. Rook, P. Porcu, S. Horwitz, S. Whittaker, Y. Tokura, M. Vermeer, P. Zinzani, L. Sokol, S. Morris, Ellen J. Kim, P. Ortiz-Romero, H. Eradat, J. Scarisbrick, A. Tsianakas, C. Elmets, S. Dalle, D. Fisher, A. Halwani, B. Poligone, J. Greer, M. Fierro, A. Khot, A. Moskowitz, A. Musiek, A. Shustov, B. Pro, L. Geskin, K. Dwyer, J. Moriya, M. Leoni, J. Humphrey, S. Hudgens, Dmitri O. Grebennik, K. Tobinai, M. Duvic   +37 more
semanticscholar   +1 more source

Cutaneous T‐cell lymphoma

International Journal of Dermatology, 1997
Jane L. Messina, Glass Lf, Cyndi Yag-Howard, Jonathan Dalton   +3 more
openaire   +3 more sources

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

The Lancet, 2017
H. Prince, Youn H. Kim, S. Horwitz, R. Dummer, J. Scarisbrick, P. Quaglino, P. Zinzani, P. Wolter, J. Sanches, P. Ortiz-Romero, O. Akilov, L. Geskin, J. Trotman, K. Taylor, S. Dalle, M. Weichenthal, J. Walewski, D. Fisher, B. Dréno, R. Stadler, T. Feldman, T. Kuzel, Yinghui Wang, M. C. Palanca-Wessels, E. Zagadailov, W. Trepicchio, Wenwen Zhang, Hui-Min Lin, Yi Liu, D. Huebner, M. Little, S. Whittaker, M. Duvic, D. Joske, H. Prince, I. Lewis, C. Jonak, F. Trautinger, O. Bechter, D. Bron, V. C. C. de Lima, J. Sanches, R. Klasa, M. Bagot, M. Beylot‐Barry, M. D’Incan, B. Dréno, F. Grange, J. Nicolay, M. Wobser, C. Assaf, C. Loquai, M. Spina, A. Bosi, P. Fattori, A. Grzanka, A. López‐Hernandez, P. Ortiz-Romero, J. R. Roca, S. Canales, T. Illidge, Rod Johnson, S. Morris, P. McKay, O. Akilov, S. Horwitz, Youn H. Kim, B. Pro, Timothy K. Kuzel, A. Lerner, H. Eradat, L. Sokol, D. C. Fisher, S. Hughey   +73 more
semanticscholar   +1 more source

Cutaneous T-Cell Lymphoma

2011
Primary cutaneous lymphomas are rare, accounting for 2% of all lymphomas. About 75% are T-cell lymphomas. There are two major subgroups within the cutaneous T-cell lymphomas (CTCL) spectrum: mycosis fungoides (MF) and Sezary syndrome (SS). MF is the prototype of CTCL. It is defined as a peripheral, epidermotropic non-Hodgkin’s T-cell lymphoma
openaire   +2 more sources

Leucoderma associated with flares of erythrodermic cutaneous T‐cell lymphomas: four cases

British Journal of Dermatology, 2000
A. Bouloc, F. Grange, M. Delfau-Larue, M. Dieng, M. Tortel, M. Avril, J. Revuz, M. Bagot, J. Wechsler, For The French Study Group Of Cutaneous Lymphomas   +9 more
semanticscholar   +1 more source

Clinicopathological and molecular study of primary cutaneous CD4+ small/medium‐sized pleomorphic T‐cell lymphoma

Journal of cutaneous pathology, 2016
S. Alberti-Violetti, C. Torres‐Cabala, R. Talpur, L. Corti, D. Fanoni, L. Venegoni, E. Berti, M. Duvic   +7 more
semanticscholar   +1 more source

Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside

Current Treatment Options in Oncology, 2016
William E. Damsky, Jaehyuk Choi
semanticscholar   +1 more source

Primary cutaneous follicular helper T‐cell lymphoma

Journal of cutaneous pathology, 2016
C. Santonja, C. Soto, R. Manso, L. Requena, M. Piris, S. Rodríguez-Pinilla   +5 more
semanticscholar   +1 more source

Cutaneous T‐Cell Lymphomas

The Journal of Dermatologic Surgery and Oncology, 1983
openaire   +2 more sources

Cutaneous T Cell Lymphomas

1999
T. Kuzel, J. Guitart, S. T. Rosen
openaire   +1 more source